Khyber Medical University to Conduct Clinical Trials for New Leishmaniasis Drug

Khyber Medical University (KMU) has taken a significant step in the fight against leishmaniasis by finalizing arrangements for the clinical trials of a new indigenously developed drug. This initiative represents a crucial advancement in medical research, offering hope for more effective treatment options for those suffering from the disease. Leishmaniasis, a disease caused by protozoan parasites transmitted by the bite of infected sandflies, poses a significant health challenge in various parts of the world, including Pakistan. The clinical trials are a part of KMU's broader efforts to enhance medical research and provide innovative solutions to pressing health issues. The university's commitment to advancing medical science is further exemplified by the construction of a new research center, which is being built at a cost of Rs1bn and is expected to become operational by the end of the current year. This center aims to provide a platform for research in various medical disciplines, thereby contributing to the overall improvement of healthcare services and outcomes.